Sydney Lupkin

speaker
938 appearances 93 recordings 3 series first heard Dec 2024 last heard 6 Sep

Sydney Lupkin’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months
21 · Jul OctJan 26AprJulnow

Recordings per month over the last 12 months — 78 in all, peaking in Jul 2026 with 21.

Appearances

newest first · ▶ plays the moment
Because it targets three hormones, GLP one, GIP, and glucagon, it's more powerful than GLP one's already on the market. matched
However, since retitrutide isn't FDA approved, matched
Compounding it, repackaging it, or selling its active ingredient to compounders is illegal, the FDA says. matched
Unapproved products may be contaminated, contain too much or too little of the active ingredient, or be counterfeit products that contain none at all. matched
Sydney Lupin, NPR News. matched
They include a medical spa chain in California and a compounding pharmacy in Texas. matched
The drug company is also suing companies that sell so-called research-only peptides online. matched
Retitrutide is currently in phase three clinical trials. matched
Because it targets three hormones, GLP1, GIP, and glucagon, it's more powerful than GLP one's already on the market. matched
However, since retitrutide isn't FDA approved, matched
Compounding it, repackaging it, or selling its active ingredient to compounders is illegal, the FDA says. matched
Sidney Lupkin, NPR News. matched
The FTC, along with two states, California and Utah, are suing HIMS and HERS.
They allege that HIMS and HERS misled customers by locking them into prescription plans as soon as they submitted medical intake forms, before they could consult with a medical provider.
And the FTC alleges HIMS and HERS made it difficult to cancel the plans.
It also alleges the company shared customers' sensitive health data despite advertising privacy to consumers.
The company also reiterated its commitment to privacy in a statement on its website.
Sydney Lepkin, NPR News.
U.S.
Under the Inflation Reduction Act, Medicare started capping patients' out-of-pocket drug spending at $2,000 last year.
Showing 161–180 of 938 · page 9 of 47 ← Previous Next →